Number of the records: 1
Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction
SYS 0133780 LBL 00000naa^^22^^^^^^^^450 005 20170308140247.9 100 $a 20170306d2017 m y0sloy0103 ba 101 0-
$a eng $d eng 102 $a SK 200 1-
$a Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction $f F. Du ... [et al.] 215 $c ilustr., grafy, tab. 320 $a Bibliogr. odkazy 320 $a Res. angl. 463 -1
$1 001 sllk_un_cat*0133080 $1 011 $a 0028-2685 $1 200 1 $a Neoplasma $e journal of experimental and clinical oncology $f Cancer Research Institute of the Slovak Academy of Sciences $v Vol. 64, no. 1 (2017), s. 108-113 $1 210 $a Bratislava $c AEPress $d 2017 $1 215 $a s. 1-166 541 1-
$a Adjuvantná chemoterapia bevacizumabom (i.p.) môže predĺžiť dobu prežívania pacientok s pokročilým nádorom vaječníkov po cytoredukci $z slo 606 1-
$3 sllk_un_auth*d010051 $a nádory vaječníkov $x chirurgia $x farmakoterapia $2 mesh 606 2-
$3 sllk_un_auth*d000230 $a adenokarcinóm $x farmakoterapia $2 mesh 606 1-
$3 sllk_un_auth*d017024 $a chemoterapia adjuvantná $2 mesh 606 1-
$3 sllk_un_auth*d000068258 $a bevacizumab $x aplikácia a dávkovanie $2 mesh 606 2-
$3 sllk_un_auth*d007274 $a injekcie intraperitoneálne $2 mesh 606 2-
$3 sllk_un_auth*d061605 $a aplikácia intravenózna $2 mesh 606 2-
$3 sllk_un_auth*d016896 $a výsledok liečby $2 mesh 606 2-
$3 sllk_un_auth*d016019 $a analýza prežívania $2 mesh 606 2-
$3 sllk_un_auth*d018572 $a prežívanie bez choroby $2 mesh 701 -1
$3 sllk_un_auth*0042446 $a Du $b F. $4 070 801 -0
$a SK $b BA006 $c 20170306 $g AACR2
Number of the records: 1